Forecast Insight: Multiple Sclerosis - Tysabri To Prevail Despite Safety Setbacks

By Author: Manjula Menon
Total Articles: 1477
Comment this article

Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increased 15.1% from 2006 to $5.3 billion in 2007.

Scope of this report

This report gives a strategic analysis of the likely impact that recent events will have on the future multiple sclerosis market

Includes multiple sclerosis-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

Provides a global market snapshot by including multiple sclerosis-specific sales analysis for leading brands outside the seven major markets

Key conclusions are supported by key opinion leader comment

Research and analysis highlights

Despite the recent confirmation of two new cases of progressive multifocal leukoencephalopathy (PML), with a much stronger 200708 enrollment rate than previously anticipated and a greater level of confidence among opinion leaders, It has upgraded its Tysabri's forecast.

It remains highly positive ...
... on Novartis's FTY720 (fingolimod). FTY720 is expected to achieve the greatest sales of all current late-stage pipeline products. However, sales growth will be restricted from 2012 by the later launch of additional oral pipeline disease-modifiers, which will represent tough direct competition.

Genzyme and Bayer Schering's alemtuzumab (Campath) has been added to this latest multiple sclerosis forecast. Potentially positioned in both the earliest stages of the disease and for rapidly progressing patients refractory on other therapies, a poor perceived safety profile and an assumed low price-point, will limit returns from this market.

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=82018

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Bharat BooK Bureau is the leading market research information aggregator which provides reports, Company profiles, newletters, country info. and online databases for the past twenty years to corportate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies. It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.